Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
Jan 12, 2023
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.
SAN DIEGO - Jan. 12, 2023 - PRLog -- About John Burd, PhD:
Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc. In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes. The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications. In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.
Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million. In 2020 DexCom had a market cap of over $40 billion. From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.
Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market. LXN was sold to Johnson and Johnson in 2000.
Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance. MAST Immunosystems was purchased by Hitachi Chemical in 1997. Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).
Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin. In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.
Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
JOHN F. BURD, Ph.D.
Founder & CEO Lysulin, Inc and Wonder Spray, llc.
4930 Bradshaw Court, San Diego, CA 92130
Phone: 619-992-2873
Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)
Learn more about Dr. Burd's products below...
Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8
Lysulin video: https://www.youtube.com/watch?v=PK3CkMty6RE
Running A1c test: https://tinyurl.com/y379jbla
Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos
Follow Burd's PR News at http://Beneficience.com
MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd
Photos: (Click photo to enlarge)
Read Full Story - Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client | More news from this source
Press release distribution by PRLog
More News
What’s the Right “Level of Care” for A.I.?
Another executive departed OpenAI, raising questions about the company’s commitment to safety.
CNN C.E.O. Mark Thompson Says He Will Stay On Under New Owner Skydance
Mark Thompson told the network’s employees that he had faith that David Ellison, the chief executive of Skydance, would support “independent news that CNN has always stood for.”
Russians Snap Up Chinese E.V.s as Ukrainian Attacks Make Fuel Scarce
As Ukraine increasingly takes the war to Russia, the effects may be most visible on the roads.
BT agrees rescue deal to buy broadband operator TalkTalk
The takeover still needs to be approved by the regulator, but would give certainty to TalkTalk's millions of customers
Why are data centres such a big deal in Scotland?
At least 23 huge data centres are planned in Scotland, causing significant concern for campaigners.
Trump chooses top spy boss to run new AI taskforce
The US president said his national intelligence chief will lead the group as worries over AI grow.
Average five-year mortgage rate hits 6% for first time in three years
The cost of a new fixed-rate mortgage has been rising in recent weeks as lenders face higher costs.
5 Challenges David Ellison Faces as He Snags His Hollywood Prize
The tech scion has given his combination of Warner Bros. Discovery and Paramount a new name: Skydance. Now he must make tough decisions about news, movies, streaming, sports and debt.
How to Get a VAT Tax Refund
Here are the steps to get your money back on VAT taxes, which are widespread in Europe and are bundled into the costs of certain items that travelers take home with them.
How to Get a VAT Tax Refund
Here are the steps to get your money back on VAT taxes, which are widespread in Europe and are bundled into the costs of certain items that travelers take home with them.
To Make More Money, Rolls-Royce Is Aiming Higher on Price, Not Production
The luxury carmaker is expanding its factory in Britain to focus on rarefied custom cars. First up is a $3.5 million-plus electric roadster.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.